Book a meeting
DO-BO

How Are UK NICE and US IRA/MFN Rewriting Global Pharma Pricing, Sreeram Ramagopalan?

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer speaks with Sreeram Ramagopalan, a global expert at the intersection of biotech value, HTA, real‑world evidence and market access. Together they unpack how the UK NICE threshold increase (from £20–30k to £25–35k per QALY) and US reforms (IRA, MFN) are quietly rewriting the rules for global launch sequencing and pricing strategy.

They discuss why the US is no longer an isolated “free pricing” island, how UK and EU prices can now feed back into US revenues, and why small and mid‑size biotechs, in particular, can no longer afford to treat US and ex‑US strategies as separate worlds.

If you’re in pharma/biotech, pricing & market access or RWE, and you’re not yet stress‑testing your global evidence, price floors and launch plan against MFN and NICE reforms, this episode is your wake‑up call.

https://www.linkedin.com/feed/update/urn:li:activity:7437804838232453120/

Related

How Can HEOR Teams Build Trust in AI-Generated Models, Haidong Feng?

By

Stefan Walzer

AI is reshaping health economics and outcomes research (HEOR) – but where does it truly belong? In this MAP episode, Dr. Stefan Walzer talks with Haidong Feng, Associate Principal Scientist at Merck, about “human in the loop” versus “AI in the loop” and why the two complement rather than contradict each other. Haidong explains why […]

Can US GLOBE and GUARD Models Really Lower Drug Prices, Brittany La Couture?

By

Stefan Walzer

When the US benchmarks drug prices against other countries, the whole world feels it. In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Brittany La Couture of Applied Policy, a health policy attorney with eight years at the Centers for Medicare & Medicaid Services, to unpack the US […]

What Will It Take to Keep Biotech Growing in Europe, Rainer Westermann?

By

Stefan Walzer

In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Rainer Westermann, Chairman of the Life Sciences Acceleration Alliance (LSAA), to ask whether Europe can remain a globally competitive home for life sciences innovation — and what has to change for new therapies to reach patients. Bringing an investor’s […]